Emergen logo.png
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
28 nov. 2023 08h17 HE | Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
27 nov. 2023 07h00 HE | Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Medicovestor Rectangle.PNG
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
20 nov. 2023 10h00 HE | Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
15 nov. 2023 07h30 HE | AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIMLogo.jpg
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
08 nov. 2023 08h45 HE | AIM ImmunoTech Inc.
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over...
Mendus_Red.png
Mendus presenterar uppdaterad data från ALISON-studien med vididencel i äggstockscancer vid SITC 2023
06 nov. 2023 02h00 HE | Mendus AB
Pressmeddelande Stockholm, 6 november 2023 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag publiceringen av uppdaterade...
Mendus_Red.png
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
06 nov. 2023 02h00 HE | Mendus AB
Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Wistar Scientists En
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer
01 nov. 2023 14h54 HE | The Wistar Institute
PHILADELPHIA, PA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith...
Elucida Oncology Logo.jpg
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
23 oct. 2023 08h00 HE | Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
Transparency Market Research
Non-Invasive Cancer Diagnostics Market Size & Share Surpass USD 207 billion by 2031, Growing at a CAGR of 7.0% - Exclusive Study by Transparency Market Research
19 oct. 2023 11h30 HE | Transparency Market Research
Wilmington, Delaware, United States, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global non-invasive cancer diagnostics market is projected to flourish at a CAGR of 7.0%...